The quality debt of clinical trials: how small operational deviations accumulate into scientific and regulatory risk

Clinical trial quality depends on several interconnected processes that protect participants and support the reliability of study data. Protocol deviations, audit findings and corrective and preventive action (CAPA) records help identify quality concerns. However, the number of recorded findings and their administrative closure status may not fully reflect the residual risk within a clinical trial. This review introduces the concept of quality debt in clinical trials to examine quality vulnerabilities that develop or persist during trial conduct. A conceptual review was undertaken using selected regulatory guidance and scientific publications addressing good clinical practice, quality by design, risk-based monitoring, protocol deviations, protocol complexity and clinical trial quality management. The literature was examined to develop a working definition and identify potential dimensions of the proposed concept. The objective was conceptual development rather than systematic evidence synthesis. Quality debt is proposed as a framework for examining residual quality risk arising from deficiencies that persist, recur, interact or remain inadequately controlled despite corrective actions. Five candidate dimensions were identified: criticality, persistence, recurrence, remediation effectiveness, interaction and residual risk. Together, these dimensions encourage consideration of the underlying quality conditions rather than relying solely on event counts or administrative closure status. Quality debt may offer an additional perspective on how unresolved quality vulnerabilities accumulate during clinical trial conduct. However, the concept remains theoretical, and its dimensions have not been operationally defined or validated. Further research is needed to determine whether it provides meaningful information beyond existing clinical trial quality-management approaches.

Authors

Publication Details

Journal
International Journal of Clinical Trials
Published
2026-11-19
DOI
https://doi.org/10.18203/2349-3259.ijct20264259
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The quality debt of clinical trials: how small operational deviations accumulate into scientific and regulatory risk

Sachin Dattram Pawar, Ajaykumar B. Malle, Pravinkumar. S. Pal
International Journal of Clinical Trials
Ethics in Clinical Research
article

The quality debt of clinical trials: how small operational deviations accumulate into scientific and regulatory risk

Sachin Dattram Pawar, Ajaykumar B. Malle, Pravinkumar. S. Pal
article en

Abstract

Clinical trial quality depends on several interconnected processes that protect participants and support the reliability of study data. Protocol deviations, audit findings and corrective and preventive action (CAPA) records help identify quality concerns. However, the number of recorded findings and their administrative closure status may not fully reflect the residual risk within a clinical trial. This review introduces the concept of quality debt in clinical trials to examine quality vulnerabilities that develop or persist during trial conduct. A conceptual review was undertaken using selected regulatory guidance and scientific publications addressing good clinical practice, quality by design, risk-based monitoring, protocol deviations, protocol complexity and clinical trial quality management. The literature was examined to develop a working definition and identify potential dimensions of the proposed concept. The objective was conceptual development rather than systematic evidence synthesis. Quality debt is proposed as a framework for examining residual quality risk arising from deficiencies that persist, recur, interact or remain inadequately controlled despite corrective actions. Five candidate dimensions were identified: criticality, persistence, recurrence, remediation effectiveness, interaction and residual risk. Together, these dimensions encourage consideration of the underlying quality conditions rather than relying solely on event counts or administrative closure status. Quality debt may offer an additional perspective on how unresolved quality vulnerabilities accumulate during clinical trial conduct. However, the concept remains theoretical, and its dimensions have not been operationally defined or validated. Further research is needed to determine whether it provides meaningful information beyond existing clinical trial quality-management approaches.

International Journal of Clinical Trials
Ethics in Clinical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon